Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye ...

Beth Marsh will lead commercialization for Neurotech, which gained FDA approval for its eye disease therapy. Neurotech in May ...

mayo.edu Idiopathic intracranial hypertension (IIH ... Of the eight with persistent visual symptoms, at least five were noted to have optic atrophy prior to stent placement. Only 41 patients who ...

Panelists discuss how treatment failure in uncomplicated urinary tract infections (UTIs) creates substantial economic burden through direct costs of additional health care visits, repeated ...

Video content above is prompted by the following: NCCN Guideline Updates on Molecular Testing BRCA testing serves 3 critical functions in ovarian cancer management: Informs treatment decisions ...

Single and multi-dose studies of the small molecule TREM2 agonist VG-3927 clear early safety hurdle. Meanwhile, new findings ...

Vulvovaginal atrophy is a frequently neglected symptom of menopause. While an estimated 10–40% of women are affected by the progressive symptoms of vaginal dryness, irritation, itching ...

Space, An Early Frontier. When a brain region is tau-negative by SUVR (green arrow, left), spatial extent (dark blue) correlates better with measures of disease severity than does SUVR (light blue).

THE absence of granulocytes from the peripheral blood is characterized by a clinical picture of overwhelming infection, involving especially the skin and mucous membranes. 1 Many cases are acute ...

Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder geographic atrophy (GA), based on feedback from the EU regulator. It is a major ...

Astellas has suffered another major setback with geographic atrophy (GA) treatment Izervay, this time in the US. The company has received a complete response letter (CRL) from the FDA for a ...